At a glance
- Originator Nonindustrial source
- Developer BTG; Nonindustrial source
- Class Antineoplastics; Radiosensitisers; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 11 Mar 2002 No development reported - Preclinical for Cancer in United Kingdom (PO)
- 27 Feb 1996 Preclinical development for Cancer in United Kingdom (PO)